In late December 2025, the BSE Healthcare Index, primarily comprising pharmaceutical companies, saw a year-to-date decline of approximately 1.5%. This performance lagged behind the Sensex, which achieved an 8.36% gain. The article highlights key themes for Indian pharma in 2025, including the cough syrup crisis, US trade relations, and research and development advancements.